Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Find Unexpected, yet invaluable treasure Excursion Rentals - 2Like many holiday traditions, lighting candles and fireplaces is best done in moderation
- 3What is Fusarium graminearum, the fungus a Chinese scientist pleaded guilty to smuggling into the US?
- 4Computerized Domains d: A Survey of \Vivid Undertakings\ Computer generated Reality Game
- 5Scientists document a death from a meat allergy tied to certain ticks
- Tens of thousands protest as far-right AfD forms new youth group
- They want better health care — so they're turning to crypto startups
- Knesset sets special panel to fast-track Karhi’s communications reform
- A decade after Brazil’s deadly dam collapse, Indigenous peoples demand justice on the eve of COP30
- A definitive Manual for Internet Mastering and Expertise Improvement
- CDC vaccine panel delays vote to stop recommending hepatitis B shot at birth
- Winter storm headed for Midwest to Northeast. Here's how much snow to expect.
- 4 well known subjects in school
- Reclassifying Achievement: Individual Accounts of Seeking after Interests
